Scientists closer to RSV vaccine Human respiratory syncytial virus vaccine looms on the horizon as clinical trials show it cuts children's risk of hospitalization by 75%. The virus provokes pneumonia in newborns, which in some cases threatens their lives.

Respiratory syncytial virus (RSV) is one of the pathogens that cause infectious lesions of the lower respiratory tract.. It is of particular danger to newborns, since the treatment of this virus is extremely limited in its capabilities.. In fact, only supportive care is offered to babies, and in some cases, the virus can lead to death.. However, babies will soon be able to receive a vaccine that reduces the risk of contracting this virus.. AstraZeneca and Sanofi are currently working on it..

Their drug has already been found to cut hospitalization rates by two-thirds in children under one year of age.. The vaccine, called nirsevimab, is a single injection that provides protection for 5 months, covering a full RSV season.. The results of the third phase of clinical trials showed fundamentally new possibilities of this drug in the formation of protection against infection..

There are currently no vaccines for the virus with a long duration of action, although research in this area has been underway for decades.. Palivizumab injections are offered to children in the high-risk category, but they provide protection against RSV for only one month, and babies need 5 injections during the season. In the UK alone, RSV causes about 30,000 hospitalizations and about 100 deaths in children under 5 years of age each year.. In the US, these figures are 58,000 and 500, respectively..

https://www. medicalforum. en/.

Keywords:.